Other Species / Isoforms
  BRF1 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
K22-ub
EVLCKGNkMLNYsAP
0 1
BRF1 (human) EVLCKGNkMLNYsAP K22-ub
BRF1 (mouse) EVLCKGNKMLNYSTP K22
BRF1 (rat) EVLCKGNKMLNYSTP K22
S27-p
GNkMLNYsAPsAGGC
0 3
BRF1 (human) GNkMLNYsAPsAGGC S27-p
BRF1 (mouse) GNKMLNYSTPSAGGC S27
BRF1 (rat) GNKMLNYSTPSAGGC S27
S30-p
MLNYsAPsAGGCLLD
0 1
BRF1 (human) MLNYsAPsAGGCLLD S30-p
BRF1 (mouse) MLNYSTPSAGGCLLD S30
BRF1 (rat) MLNYSTPSAGGCLLD S30
K39-ub
GGCLLDRkAVGtPAG
0 1
BRF1 (human) GGCLLDRkAVGtPAG K39-ub
BRF1 (mouse) GGCLLDRKAVGTPAG K39
BRF1 (rat) GGCLLDRKAVGTPAG K39
T43-p
LDRkAVGtPAGGGFP
0 3
BRF1 (human) LDRkAVGtPAGGGFP T43-p
BRF1 (mouse) LDRKAVGTPAGGGFP T43
BRF1 (rat) LDRKAVGTPAGGGFP T43
S54-p
GGFPRRHsVtLPSSk
Upstream
Downstream
3 49
Effects on Modified Protein
  • activity, induced
  • molecular association, regulation
  • protein stabilization
Effects on Biological Processes:
  • cell growth, inhibited
  • transcription, altered
Kinase, in vitro:
  • MAPKAPK2 (human)
  • PKACA (human)
Putative in vivo kinases:
  • MAPKAPK2 (human)
  • PKACA (human)
Treatment
  • ACTH
  • anisomycin
  • EGF
  • hypoxia
  • okadaic_acid
  • SB202190
BRF1 (human) GGFPRRHsVtLPSSk S54-p
BRF1 (mouse) GGFPRRHsVtLPSSK S54-p
BRF1 (rat) GGFPRRHsVTLPSSK S54-p
T56-p
FPRRHsVtLPSSkFH
0 2
BRF1 (human) FPRRHsVtLPSSkFH T56-p
BRF1 (mouse) FPRRHsVtLPSSKFH T56-p
BRF1 (rat) FPRRHsVTLPSSKFH T56
K61-ub
sVtLPSSkFHQNQLL
0 2
BRF1 (human) sVtLPSSkFHQNQLL K61-ub
BRF1 (mouse) sVtLPSSKFHQNQLL K61
BRF1 (rat) sVTLPSSKFHQNQLL K61
S70
HQNQLLSSLkGEPAP
0 1
BRF1 (human) HQNQLLSSLkGEPAP S70
BRF1 (mouse) HQNQLLSsLKGEPAP S70-p
BRF1 (rat) HQNQLLSSLKGEPAP S70
K72-ub
NQLLSSLkGEPAPAL
0 5
BRF1 (human) NQLLSSLkGEPAPAL K72-ub
BRF1 (mouse) NQLLSsLKGEPAPSL K72
BRF1 (rat) NQLLSSLKGEPAPTL K72
K72-sm
NQLLSSLkGEPAPAL
0 1
BRF1 (human) NQLLSSLkGEPAPAL K72-sm
BRF1 (mouse) NQLLSsLKGEPAPSL K72
BRF1 (rat) NQLLSSLKGEPAPTL K72
S90-p
DSRFRDRsFsEGGER
0 11
BRF1 (human) DSRFRDRsFsEGGER S90-p
BRF1 (mouse) DSRFRDRsFsEGGER S90-p
BRF1 (rat) DSRFRDRSFsEGGER S90
S92-p
RFRDRsFsEGGERLL
Upstream
Downstream
4 21
Effects on Modified Protein
  • intracellular localization
  • molecular association, regulation
  • protein stabilization
Effects on Biological Processes:
  • RNA stability, altered
  • cell growth, inhibited
  • transcription, altered
Kinase, in vitro:
  • Akt1 (human)
  • MAPKAPK2 (human)
Putative in vivo kinases:
  • Akt1 (human)
  • MAPKAPK2 (human)
Treatment
  • anisomycin
  • insulin
  • ischemia
  • vemurafenib
  • wortmannin
BRF1 (human) RFRDRsFsEGGERLL S92-p
BRF1 (mouse) RFRDRsFsEGGERLL S92-p
BRF1 (rat) RFRDRSFsEGGERLL S92-p
K103-ac
ERLLPTQkQPGGGQV
0 3
BRF1 (human) ERLLPTQkQPGGGQV K103-ac
BRF1 (mouse) ERLLPTQKQPGSGQV K103
BRF1 (rat) ERLLPTQKQPGSGQV K103
K103-ub
ERLLPTQkQPGGGQV
0 12
BRF1 (human) ERLLPTQkQPGGGQV K103-ub
BRF1 (mouse) ERLLPTQkQPGSGQV K103-ub
BRF1 (rat) ERLLPTQKQPGSGQV K103
Y115-p
GQVNSSRyKTELCRP
Upstream
0 2
Regulatory protein:
  • FGFR1 (human)
BRF1 (human) GQVNSSRyKTELCRP Y115-p
BRF1 (mouse) GQVNSSRYKTELCRP Y115
BRF1 (rat) GQVNSSRYKTELCRP Y115
K130-ub
FEENGACkYGDkCQF
0 1
BRF1 (human) FEENGACkYGDkCQF K130-ub
BRF1 (mouse) FEENGACKYGDKCQF K130
BRF1 (rat) FEENGACKYGDKCQF K130
K134-ub
GACkYGDkCQFAHGI
0 1
BRF1 (human) GACkYGDkCQFAHGI K134-ub
BRF1 (mouse) GACKYGDKCQFAHGI K134
BRF1 (rat) GACKYGDKCQFAHGI K134
S192-p
LAGARDLsADRPRLQ
0 5
BRF1 (human) LAGARDLsADRPRLQ S192-p
BRF1 (mouse) LAGGRDLsADRPRLQ S192-p
BRF1 (rat) LAGGRDLSADRPRLQ S192
S201-p
DRPRLQHsFsFAGFP
0 1
BRF1 (human) DRPRLQHsFsFAGFP S201-p
BRF1 (mouse) DRPRLQHSFSFAGFP S201
BRF1 (rat) DRPRLQHSFSFAGFP S201
S203-p
PRLQHsFsFAGFPSA
Upstream
Downstream
3 21
Effects on Modified Protein
  • molecular association, regulation
  • protein stabilization
Effects on Biological Processes:
  • RNA stability, altered
  • cell growth, inhibited
  • transcription, altered
Kinase, in vitro:
  • Akt1 (human)
  • MAPKAPK2 (human)
Putative in vivo kinases:
  • MAPKAPK2 (human)
Treatment
  • 4-HT
  • anisomycin
  • MK2_inhibitor_III
  • okadaic_acid
BRF1 (human) PRLQHsFsFAGFPSA S203-p
BRF1 (mouse) PRLQHSFSFAGFPSA S203
BRF1 (rat) PRLQHSFSFAGFPSA S203
S283-p
TFLFRPMsESPHMFD
0 1
BRF1 (human) TFLFRPMsESPHMFD S283-p
BRF1 (mouse) TFLFRPMSESPHMFD S283
BRF1 (rat) TFLFRPMSESPHMFD S283
S314-p
SSSSSSHsGsDsPTL
0 1
BRF1 (human) SSSSSSHsGsDsPTL S314-p
BRF1 (mouse) SSSSSSHSGSDSPTL S314
BRF1 (rat) SSSSSSHSGSDSPTL S314
S316-p
SSSSHsGsDsPTLDN
0 1
BRF1 (human) SSSSHsGsDsPTLDN S316-p
BRF1 (mouse) SSSSHSGSDSPTLDN S316
BRF1 (rat) SSSSHSGSDSPTLDN S316
S318-p
SSHsGsDsPTLDNSR
0 1
BRF1 (human) SSHsGsDsPTLDNSR S318-p
BRF1 (mouse) SSHSGSDSPTLDNSR S318
BRF1 (rat) SSHSGSDSPTLDNSR S318
S331-p
SRRLPIFsRLsIsDD
0 5
BRF1 (human) SRRLPIFsRLsIsDD S331-p
BRF1 (mouse) SRRLPIFsRLsIsDD S331-p
BRF1 (rat) SRRLPIFSRLsISDD S331
S334-p
LPIFsRLsIsDD___
Upstream
Downstream
2 29
Effects on Modified Protein
  • activity, induced
  • protein stabilization
Effects on Biological Processes:
  • RNA stability, inhibited
  • carcinogenesis, inhibited
  • cell adhesion, inhibited
  • cell cycle regulation
  • cell growth, inhibited
  • cell motility, inhibited
  • transcription, inhibited
Kinase, in vitro:
  • PKACA (human)
Putative in vivo kinases:
  • PKACA (human)
Treatment
  • ACTH
  • anti-CD3
  • hypoxia
  • okadaic_acid
BRF1 (human) LPIFsRLsIsDD___ S334-p
BRF1 (mouse) LPIFsRLsIsDD___ S334-p
BRF1 (rat) LPIFSRLsISDD___ S334-p
S336-p
IFsRLsIsDD_____
0 3
BRF1 (human) IFsRLsIsDD_____ S336-p
BRF1 (mouse) IFsRLsIsDD_____ S336-p
BRF1 (rat) IFSRLsISDD_____ S336